niacinamide has been researched along with iohexol in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Lieber, ML; Remer, EM; Rini, BI; Shah, SN; Smith, AD | 1 |
| de Ruysscher, D; Dingemans, AM; Lind, JS; Meijerink, MR; Ollers, MC; Postmus, PE; Smit, EF; van Kuijk, C | 1 |
| Glushkov, SI; Karpishchenko, SN; Zheregelia, SN | 1 |
| Bruns, CJ; Clevert, DA; Cyran, CC; Dietrich, O; Eschbach, R; Hinkel, R; Ingrisch, M; Nikolaou, K; Paprottka, PM; Reiser, MF; Schwarz, B; von Einem, JC; Wintersperger, BJ | 1 |
| Chen, J; Gao, D; Li, W; Liu, N; Zheng, D | 1 |
1 trial(s) available for niacinamide and iohexol
| Article | Year |
|---|---|
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Female; Humans; Iohexol; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
5 other study(ies) available for niacinamide and iohexol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
[Using cytoflavin for correcting x-ray contrasting agent-induced nephropathy].
Topics: Animals; Contrast Media; Cytoprotection; Drug Combinations; Flavin Mononucleotide; Inosine Diphosphate; Iohexol; Kidney Diseases; Male; Niacinamide; Rats; Succinates | 2010 |
Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Cell Line, Tumor; Contrast Media; Iohexol; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Rats; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Statistics as Topic; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Astaxanthin attenuates contrast agent-induced acute kidney injury in vitro and in vivo via the regulation of SIRT1/FOXO3a expression.
Topics: Acute Kidney Injury; Animals; Apoptosis; bcl-2-Associated X Protein; Blood Urea Nitrogen; Caspase 3; Catalase; Cell Line; Cell Proliferation; Contrast Media; Creatinine; Epithelial Cells; Forkhead Box Protein O3; Glutathione; Glutathione Peroxidase; Humans; Iohexol; Kidney Tubules, Proximal; Male; Malondialdehyde; Niacinamide; Peptides; Proto-Oncogene Proteins c-bcl-2; Rats; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Sirtuin 1; Superoxide Dismutase; Vitamin B Complex; Xanthophylls | 2018 |